Anna K. Slocum et al., 2026-04-22: Case report of a 49-year-old woman with stage IV HR+/HER2- breast cancer treated in Istanbul with metabolically supported chemotherapy plus six repurposed drugs including ivermectin 6 mg/day, reported in sustained remission beyond three years.
mebendazole (100 mg/day), an anthelmintic that disrupts microtubules and induces apoptosis in cancer cells; ivermectin (6 mg/day), which can block Wnt/β-catenin and AKT/mTOR signaling
Anna K. Slocum et al., 2026-04-22: Case report of a 49-year-old woman with stage IV HR+/HER2- breast cancer treated in Istanbul with metabolically supported chemotherapy plus six repurposed drugs including ivermectin 6 mg/day, reported in sustained remission beyond three years. C3. Study type: single case report, n=1, patient from Italy treated in Turkiye (ChemoThermia Oncology Center, Istanbul; Boston College). No comparator. Dose: ivermectin 6 mg/day, with metformin 1000 mg/day, aspirin 100 mg/day, doxycycline 100 mg/day, mebendazole 100 mg/day and famotidine (dose in the full text). Other treatment: docetaxel/doxorubicin/cyclophosphamide under 14-hour fast with insulin-induced mild hypoglycaemia, ketogenic diet (GKI<2.0), local and whole-body hyperthermia, hyperbaric oxygen. Outcome as measured: PET-CT at 3 months showed reduced tumour burden; at 6 months near complete response with resolution of active bone metastases; sustained remission as of January 2026 (over three years), ECOG 0. Funding: not stated. Disclosures: 'The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.' Note that co-author Seyfried has published extensively on ketogenic metabolic therapy. Effect cannot be attributed to ivermectin. Study type: case report.
